Clinical trials: Philadelphia Chromosome Negative
Healthy Volunteers
AZD4635 Relative Bioavailability Study
To investigate the pharmacokinetics and relative bioavailability of AZD4635 solid oral formulation and compare with the nano-suspension reference formulation with the option to assess food effect, pH effect and absolute…
- Trial name
- Rel Bio (NCT03710434)
- Testing
- AZD4635 50 mg nano-suspension (reference), AZD4635 solid oral formulation - fasted, AZD4635 solid oral formulation - fed
- Where
- United Kingdom
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Metabolic Dysfunction-associated Steatotic Liver Disease
Digital Pathology and AI for Liver Outcomes in MASLD (DPAILO-2)
The aim of this multi-center, retrospective epidemiologic study is to confirm the prognostic performance of the Digital Pathology (DP) FibroNest Phenotypic Fibrosis Composite Score (Ph-FCS), derived from standard digital…
- Trial name
- NCT06493253
- Testing
- Digital Pathology FibroNest Phenotypic Fibrosis Composite Score (Ph-FCS)
- Where
- United States
- Volunteers
- 1,519 people
- Sponsor
- PharmaNest, Inc
Spondylitis, Ankylosing
A Study of RoActemra/Actemra (Tocilizumab) in Patients With Ankylosing Spondylitis Who Have Failed Treatment With NSAIDs
This randomized, double-blind, placebo-controlled study will evaluate the safety and efficacy of RoActemra/Actemra (tocilizumab) in patients with ankylosing spondylitis (AS) who have failed treatment with non-steroidal…
- Trial name
- NCT01209702
- Testing
- tocilizumab
- Where
- 139 sites in United States, Australia and 16 more
- Volunteers
- 306 people
- Sponsor
- Hoffmann-La Roche
Vaginal Health, Vaginal pH
A Single Group Study to Evaluate the Effects of a Probiotic Vaginal Suppository on Vaginal Health.
This is a virtual single-group clinical trial lasting 8 weeks to evaluate the effects of a probiotic vaginal suppository on vaginal health.
- Trial name
- NCT06565312
- Testing
- Flora Power Probiotic Vaginal Suppository
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Love Wellness
Systemic Lupus Erythematosus, Arthritic Psoriasis
A Study to Evaluate BMS-986165 Tablet Formulation Relative to BMS-986165 Capsule Formulation and the Effect of a High-Fat/ High-Calorie Meal and Increased Gastric pH on the BMS-986165 Tablet Formulation
The purpose of this study is to evaluate BMS-986165 tablet formulation versus BMS-986165 capsule formulation. This study will also evaluate the effect of a high-fat/ high-calorie meal and increased gastric pH on the BMS-986165…
- Conditions
- Systemic Lupus Erythematosus, Arthritic Psoriasis, Psoriasis, Inflammatory Bowel Diseases
- Trial name
- NCT03254784
- Testing
- BMS-986165 Capsule, BMS-986165 Tablet
- Where
- United States
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Pharmacodynamics Study
Study to Assess the Pharmacodynamics/Pharmacokinetics After Repeated Dosing of D961H 10 mg and Omeprazole 10 mg in Japanese Healthy Male Subjects
The purpose of this study is to assess the pharmacodynamics (intragastric pH) after repeated oral administration of D961H 10 mg and omeprazole 10 mg in Japanese healthy male subjects who are classified by the genotype of CYP2C19…
- Trial name
- NCT01159145
- Testing
- D961H, Omeprazole
- Where
- Japan
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Chronic Myeloid Leukemia, Philadelphia Chromosome
Study of Chinese Newly Diagnosed Participants With Philadelphia Chromosome-Positive (Ph+) Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
Observational medical record review of newly diagnosed CML-CP participants in China
- Conditions
- Chronic Myeloid Leukemia, Philadelphia Chromosome, Chronic Myeloid Leukemia in Chronic Phase
- Trial name
- NCT03509896
- Testing
- Non-Interventional
- Where
- China
- Volunteers
- 463 people
- Sponsor
- Bristol-Myers Squibb
Arthritis, Rheumatoid
An Oral p38 Inhibitor Investigating Safety, Efficacy, And PK In Subjects With Active Rheumatoid Arthritis
Investigating the safety and tolerability of a p38 inhibitor as monotherapy in subjects who have failed at least 1 DMARD.
- Trial name
- NCT00383188
- Testing
- PH-797804
- Where
- 48 sites in Australia, Brazil and 10 more
- Volunteers
- 305 people
- Sponsor
- Pfizer
Healthy Subjects
A Ph 1 Study of Epanova® in Healthy Chineses
The purpose of this study is to explore the safety, tolerability, and PK of single and multiple doses of Epanova in healthy male and female Chinese subjects and to allow comparison of these parameters with the Western population…
- Trial name
- NCT03574142
- Testing
- Epanova
- Where
- China
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Protein Losing Enteropathy
Pilot/Ph I Safety and Efficacy of ODSH in Protein Losing Enteropathy Secondary to Single Ventricle Palliative Surgery
Protein Losing Enteropathy (PLE) is a serious medical condition that may develop in children and adults with congenital heart disease for which a palliative procedure known as the "Fontan procedure" has been performed.
- Trial name
- NCT01161641
- Testing
- ODSH at 0.125 mg/kg/h, ODSH at 0.375 mg/kg/h, ODSH at 0.250 mg/kg/h
- Where
- 4 sites in United States
- Volunteers
- 5 people
- Sponsor
- Jazz Pharmaceuticals
Breast Cancer
Ph II Early BC Pre-Surgical Biologic Study
A pre-surgery study to assess changes that occur in human breast cancer material and normal skin after a short course of treatment with Iressa.
- Trial name
- NCT00637026
- Testing
- Gefitinib
- Volunteers
- 65 people
- Sponsor
- AstraZeneca
Philadelphia Chromosome Positive Chronic Myelogenous Leukemia
Nilotinib and LDE225 in the Treatment of Chronic or Accelerated Phase Myeloid Leukemia in Patients Who Developed Resistance to Prior Therapy
The purpose of this study is to determine the feasibility of administering the combination of nilotinib and LDE225 to patients with chronic or accelerated phase of chronic myeloid leukemia and to establish the maximum tolerated…
- Trial name
- NCT01456676
- Testing
- Nilotinib + LDE225
- Where
- 7 sites in Canada, France and 3 more
- Volunteers
- 11 people
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Hypertension Associated With HFpEF
Long-Term Open-Label Extension Study of Oral Levosimendan
The purpose of this study is to provide continued access to treatment with oral levosimendan (TNX-103) and to describe the safety of continued use of TNX-103 in participants with pulmonary hypertension with heart failure with…
- Trial name
- NCT07436689
- Testing
- TNX-103
- Where
- 10 sites in United States
- Volunteers
- 800 people
- Sponsor
- Tenax Therapeutics, Inc.
Pulmonary Hypertension, Interstitial Lung Disease
An Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
The primary objective of this study is to evaluate the safety and tolerability of the long-term use of TPIP in participants with PH-ILD from Study INS1009-311 (NCT07179380).
- Trial name
- NCT07234032
- Testing
- Treprostinil Palmitil Inhalation Powder
- Where
- 9 sites in United States, Japan and 3 more
- Volunteers
- 344 people
- Sponsor
- Insmed Incorporated
Idiopathic Pulmonary Fibrosis, Pulmonary Hypertension
ARTEMIS-PH - Study of Ambrisentan in Subjects With Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis
Ambrisentan is an endothelin receptor antagonist used for the treatment of pulmonary hypertension (PH). Based on research suggesting a role for endothelin-1 in the pathogenesis of idiopathic pulmonary fibrosis (IPF) and the poor…
- Trial name
- ARTEMIS-PH (NCT00879229)
- Testing
- Ambrisentan
- Where
- 85 sites in United States, Australia and 5 more
- Volunteers
- 40 people
- Sponsor
- Gilead Sciences
Multiple Myeloma
Ph 1b Study to Evaluate GSK2110183 in Combination With Bortezomib and Dexamethasone in Subjects With Multiple Myeloma
Phase Ib, open-label study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and clinical activity of GSK2110183 dosed in combination with bortezomib and dexamethasone in multiple myeloma (MM)…
- Trial name
- PKB115125 (NCT01428492)
- Testing
- GSK2110183, Bortezomib, Dexamethasone
- Where
- 13 sites in United States, Australia and 3 more
- Volunteers
- 90 people
- Sponsor
- Novartis
Healthy
Pharmacokinetics of Dipyridamole Administered as Aggrenox® (Dipyridamole Extended Release Plus Aspirin) Capsule Versus Dipyridamole Immediate Release Plus Aspirin Following Alteration of Stomach pH
Comparison of pharmacokinetics of dipyridamole administered as Aggrenox versus dipyridamole administered as the immediate release formulation plus aspirin, under conditions of reduced stomach acidity.
- Trial name
- NCT02251184
- Testing
- Aggrenox, Dipyridamole, Aspirin
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Diabetes, Healthy
Effect of Liraglutide on Gastrointestinal Absorption of Several Drugs and Potential Influence of Liraglutide on Intragastric pH
The trial is conducted in Europe. The aim of the trial is to investigate if there is any drug to drug interaction between liraglutide and atorvastatin (Lipitor®), lisinopril (Zestril®), griseofulvin and digoxin (Lanoxin®).
- Trial name
- NCT01518166
- Testing
- liraglutide, atorvastatin, lisinopril
- Where
- Sweden
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia
A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)
This study will assess the pharmacokinetics of nilotinib in Ph+ CML pediatric patients that are newly diagnosed or resistant or intolerant to imatinib or dasatinib or refractory or relapsed Ph+ ALL compared to the adult…
- Trial name
- NCT01077544
- Testing
- Nilotinib
- Where
- 12 sites in France, Italy and 2 more
- Volunteers
- 15 people
- Sponsor
- Novartis Pharmaceuticals
Risky Sexual Behavior, Emotion Regulation
An Interactive Education Program to Reduce High Risk Behavior in Adolescents Ph II (iTRAC HERO)
Using the efficacious iTRAC intervention to enhance emotion regulation competencies as a foundation, this study will create and test iTRAC-HERO to teach emotion regulation skills in the context of sexual health education.
- Conditions
- Risky Sexual Behavior, Emotion Regulation, Adolescent Behavior
- Trial name
- iTRAC-HERO (NCT06894277)
- Testing
- iTRAC-HERO
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Klein Buendel, Inc.